Glutamate/NMDA antagonists may help to reinstate normal responses to levodopa with attenuation of dyskinesias [214-216] by decreasing the activity of glutamatergic projections, an action similar to CB1 agonists in the striatum. This evidence concerns the gene CNR1 and Dyskinesia.